公开(公告)号：US20230277533A1

公开(公告)日：2023-09-07

申请号：US17904159

申请日：2021-02-12

申请人： KSQ Therapeutics, Inc.

发明人： Andrew Alistair WYLIE ,  Solomon Martin SHENKER ,  Pamela Jean SULLIVAN ,  Frank STEGMEIER ,  Anne Louise CADZOW ,  Hanlan LIU ,  Kerstin Wolf SINKEVICIUS

IPC分类号： A61K31/502 ,  A61K31/454 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5025 ,  A61P35/00

CPC分类号： A61K31/502 ,  A61K31/454 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5025 ,  A61P35/00

摘要： The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.

公开(公告)号：US20230203046A1

公开(公告)日：2023-06-29

申请号：US18045770

申请日：2022-10-11

申请人： KSQ Therapeutics, Inc.

发明人： Jehrod Burnett BRENNEMAN ,  Elsa Beyer KRALL ,  Michael SCHLABACH ,  Andrew Alistair WYLIE

IPC分类号： C07D487/04 ,  A61P35/00 ,  C12Q1/6886

CPC分类号： C07D487/04 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/156

摘要： The present disclosure provides compounds having Formula I:




and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5′, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

公开(公告)号：US20210115049A1

公开(公告)日：2021-04-22

申请号：US16721079

申请日：2019-12-19

申请人： KSQ Therapeutics Inc.

发明人： Jehrod Burnett BRENNEMAN ,  Elsa Beyer KRALL ,  Michael SCHLABACH ,  Andrew Alistair WYLIE

IPC分类号： C07D487/04 ,  A61P35/00 ,  C12Q1/6886

摘要： The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5′, R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.